Komori
Earnings4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

(Correction) Partial Correction to the Summary of Financial Results for the Fiscal Year Ended March 2025 (Japanese GAAP) (Non-consolidated)

The gain on sale of investment securities stated in the overview of results in the summary of financial results has been corrected from ¥491 million to ¥419 million. This correction has no impact on earnings.

Worth reading
64In focus
Scored from 2 of 3 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
72
百万円(投資有価証券売却益の記載額の減少)
Wording
Definitive
How definitive the wording is.

What was corrected and how

A subsequent correction by the company to the contents of an already published filing.

Original disclosure15 May 2025

2025 年 3 月期 決算短信〔日本基準〕(非連結)

Open the original document
12 daysThe pre-correction wording stayed published for this period (Calculated from the Original Disclosure Date Indicated in the Document)
This correction2025-05-27
Location of correction (where in the original document)

添付資料2ページ 1.経営成績等の概況 (1)当期の経営成績の概況

Before correction

4億9千1百万円

After correction

4億 1 千 9 百万円

Impact on Business Performance (the company’s explanation)

This correction has no impact on earnings.

Reason for correction

「2025 年 3 月期 決算短信〔日本基準〕(非連結)」提出後に、記載内容の一部に誤りがあることが判明したため。

What was corrected and how
ItemDetails
Disclosure subject to correction2025 年 3 月期 決算短信〔日本基準〕(非連結)
Original disclosure date15 May 2025
Location of correction添付資料2ページ 1.経営成績等の概況 (1)当期の経営成績の概況
Details of correction4億9千1百万円 → 4億 1 千 9 百万円
Reason for correction「2025 年 3 月期 決算短信〔日本基準〕(非連結)」提出後に、記載内容の一部に誤りがあることが判明したため。
Impact on Business PerformanceThis correction has no impact on earnings.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

After the Summary of Financial Results was submitted, it was discovered that part of the information disclosed was incorrect.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
(Correction) Partial Correction to the Summary of Financial Results for the Fiscal Year Ended March 2025 (Japanese GAAP) (Non-consolidated) | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori